Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
ADBiotech Pushes Back Convertible Bond Payment Date to Nov. 11

ADBiotech Pushes Back Convertible Bond Payment Date to Nov. 11

BitgetBitget2026/11/03 21:07
  • ADBiotech corrected terms for its KRW 1 billion convertible bond issue, delaying payment to Nov. 11, 2026, from Nov. 6.
  • Maturity moves to Nov. 11, 2029; interest payments switch from quarterly to monthly at an unchanged 6% annual coupon.
  • New conversion-price resets apply every seven months, with a KRW 1,400 floor versus the initial KRW 1,999 conversion price.
  • The annual call-option premium rises to 6.5% from 6%.
  • Added collateral provisions require security equivalent to 120% of the bonds’ registered amount within one month of issuance.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADBiotech Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261103000389), on November 04, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss